Aims and Scope
Cellular Therapy and Transplantation is published since 2008 as an international edition initiated by European specialists in Hematology, Transplantation and Cellular Therapy. The Journal is aimed for publication of novel results and ideas in the field of transplantation, cellular therapy, hematology and oncology obtained by Russian- and English-speaking clinicians and scientists, with young generation of hematologists being in scope, in order to spread these new data among the international community involved into the stem cell treatment of blood disorders and cell transplantation science.
The following submissions could be considered at the CTT Journal:
- Review articles
- Clinical Studies
- Clinical cases
- Experimental studies
- Short communications
- Letters to the Editor
- Conference overviews
Peer Review Process
All manuscripts submitted to the editorial staff of Cellular Therapy and Transplantation are a subject for BLIND peer-reviewing. This implies that the reviewer is anonymous to the author(s).
1. The editor(s) will perform an initial review of all submitted manuscripts and may reject papers that are clearly outside of the scope of the journal. Manuscripts within the scope will be sent to AT LEAST TWO reviewers.
2. We select peer-reviewers from the editorial board members and leading international/ Russian experts in the relevant areas of medicine.
3. We aim to limit the review process to 2-4 weeks, though in some cases the schedule may be adjusted at the reviewer’s request, or a need for additional reviewing.
4. Reviewer has an option to refuse the assessment should any conflict of interests arise and may affect perception or interpretation of the manuscript contents.
5. Upon review completion, the reviewer is expected to present the editorial board with one of the following recommendations:
– to accept the paper in its present state;
– to invited the author to make minor revisions of their manuscript to address specific concerns before final decision is reached;
– that final decision be reached following major revisions and review by another specialist;
– to reject the manuscript outright.
6. If the reviewer has recommended any refinements, the editorial staff would advise the author either to implement the corrections, or to dispute them reasonably. Authors are kindly required to limit their revision within 2 months and to resubmit the adapted manuscript within this period for final evaluation.
7. Should the authors decide to refuse from publishing the manuscript, they shall notify the editor in writing. In case the author fails to do so within 3 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.
8. If author and reviewers encounter insoluble contradictions regarding revision of the manuscript, additional review may be considered. In such situations, he editor-in-chief resolves the conflict getting the editorial board involved if required.
9. The editorial board of Cellular Therapy and Transplantation reaches final decision to reject a manuscript according to reviewers’ recommendations, and duly notifies the authors.
10. Upon the decision to accept the manuscript for publishing, the editorial staff notifies the authors of the scheduled date of publication.
11. Original reviews of submitted manuscripts remain deposited for 3 years.
ISSN 1867-416X (Print)
ISSN 1866-8836 (Online)
Cellular Therapy and Transplantation is a quarterly Journal (4 issues a year).
Open Access Policy
The papers accepted for publication in CTT are made available on the Journal site at no charge to readers (Open Access). The articles published in CTT are provided under the following license: Creative Commons Attribution 3.0 Unported, http://creativecommons.org/licenses/by/3.0/ Authors retain the copyright for their contributions.
The journal makes full-text archives under the following national initiatives: the full text-versions of CTT are available at the Journal site http://www.cttjournal.com and at the Web portal elibrary.ru
Articles in Cellular Therapy and Transplantation are indexed by the following databases:
- Google Scholar
- RINC (Russian Index of Scientific Citation on the www.elibrary.ru platform)
The Publication Ethics and Publication Malpractice Statement of Cellular Therapy and Transplantation are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org, and requirements for peer-reviewed medical journals, elaborated by the Elsevier Publishing House (in accordance with international ethical rules of scientific publications).
1.1. The publication in a peer reviewed learned journal serves many purposes outside of simple communication. It is a building block in the development of a coherent and respected network of knowledge. For all these reasons and more it is important to lay down standards of expected ethical behaviour by all parties involved in the act of publishing: the author, the journal editor, the peer reviewer, the publisher and the society for society-owned or sponsored journal: Cellular Therapy and Transplantation.
1.2. Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in its publications.
1.3. Publisher takes its duties of guardianship over the scholarly record extremely seriously. Our journal programmes record «the minutes of science» and we recognise our responsibilities as the keeper of those «minutes» in all our policies not least the ethical guidelines that we have here adopted.
2. Duties of Editors
2.1. Publication decision – The Editor of Cellular Therapy and Transplantation is solely and independently responsible for deciding which of the articles submitted to the journal should be published, often working on conjunction with the relevant society (for society-owned or sponsored journals). The validation of the work in question and its importance to researchers and readers must always underwrite such decisions. The Editor may be guided by the policies of the Cellular Therapy and Transplantation editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers (or society officers) in making this decision.
2.2. Fair play – An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.
2.3. Confidentiality – The editor and any editorial staff of Cellular Therapy and Transplantation must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
2.4. Disclosure and Conflicts of interest
2.4.1. Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers.
2.5. Vigilance over published record – An editor presented with convincing evidence that the substance or conclusions of a published paper are erroneous should coordinate with the publisher (and/or society) to promote the prompt publication of a correction, retraction, expression of concern, or other note, as may be relevant.
2.6. Involvement and cooperation in investigations – An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies.
3. Duties of Reviewers
3.1. Contribution to Editorial Decisions – Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.
3.2. Promptness – Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor of Cellular Therapy and Transplantation and excuse himself from the review process.
3.3. Confidentiality – Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorised by the editor.
3.4. Standard and objectivity – Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.
3.5. Acknowledgement of Sources – Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
3.6. Disclosure and Conflict of Interest
3.6.1. Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
3.6.2. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
4. Duties of Authors
4.1. Reporting standards
4.1.1. Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behaviour and are unacceptable.
4.1.2. Review and professional publication articles should also be accurate and objective, and editorial 'opinion’ works should be clearly identified as such.
4.2. Data Access and Retention – Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.
4.3.Originality and Plagiarism
4.3.1. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted.
4.3.2. Plagiarism takes many forms, from ‘passing off’ another’s paper as the author’s own paper, to copying or paraphrasing substantial parts of another’s paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behaviour and is unacceptable.
4.4. Multiple, Redundant or Concurrent Publication
4.4.1. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.
4.4.2. In general, an author should not submit for consideration in another journal a previously published paper.
4.4.3. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. Further detail on acceptable forms of secondary publication can be found at www.icmje.org.
4.5. Acknowledgement of Sources – Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.
4.6. Authorship of the Paper
4.6.1. Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.
4.6.2. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
4.7. Hazards and Human or Animal Subjects
4.7.1. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.
4.7.2. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
4.8. Disclosure and Conflicts of Interest
4.8.1. All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.
4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.
4.9. Fundamental errors in published works – When an author discovers a significant error or inaccuracy in a published work, it is the author’s obligation to promptly notify the editor of Cellular Therapy and Transplantation Journal and cooperate with Publisher to retract or correct the paper, If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper.
5. Duties of the Publisher (and if relevant, Society)
5.1. Publisher should adopt policies and procedures that support editors, reviewers and authors of Cellular Therapy and Transplantation in performing their ethical duties under these ethics guidelines. The publisher should ensure that the potential for advertising or reprint revenue has no impact or influence on editorial decisions.
5.2. The publisher should support Cellular Therapy and Transplantation journal editors in the review of complaints raised concerning ethical issues and help communications with other journals and/or publishers where this is useful to editors.
5.3. Publisher should develop codes of practice and inculcate industry standards for best practice on ethical matters, errors and retractions.
5.4. Publisher should provide specialised legal review and counsel if necessary. The section is prepared according to the files (http://health.elsevier.ru/attachments/editor/file/ethical_code_final.pdf) of Elsevier Publisher (https://www.elsevier.com/) and files (http://publicationethics.org/resources) from Committee on Publication Ethics (COPE - http://publicationethics.org/).
• Hamburg University, Germany
• First St.Petersburg State Medical I.Pavlov University, St. Petersburg, Russia
• Foundation for Development of Bone Marrow Transplantation, St. Petersburg, Russia
Cellular Therapy and Transplantation doesn't have any article processing charges. The journal doesn't have any article submission charges. The СТТ Journal doesn't pay fees to authors of articles and reviewers.
Disclosure and Conflict of Interest
Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
Cellular Therapy and Transplantation uses Antiplagiat software. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.
Preprint and Postprint Policy
As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in Cellular Therapy and Transplantation we suggest that the link to the article on journal's website is used when the article is shared on personal or public websites. Postprint – The final version of an academic article or other publication – after it has been peer-reviewed and revised into its final form by the author. As a general term this covers both the author's final version and the version as published, with formatting and copy-editing changes in place.
1. All advertisements and commercially sponsored publications are independent from editorial decisions. Publishers does not endorse any product or service marked as an advertisement or promoted by a sponsor in Publishers publications. Editorial content is not compromised by commercial or financial interests, or by any specific arrangements with advertising clients or sponsors.
2. Publishers reserves the right to decline any type of advertising that is damaging to the brand of Publishers or is inappropriate to the content held on the Publishers network.
3. Publishers will not accept advertising for products or services known to be harmful to health (e.g. tobacco and alcohol products).
4. Advertisements may not be deceptive or misleading, and must be verifiable. Advertisements should clearly identify the advertiser and the product or service being offered.
5. Publishers will not allow any treatment-specific or drug-specific campaign to be targeted to a specific article(s) or on any page where content relates to the product(s) being advertised. (Advertisers may not link to articles using keywords; they may not target advertising for a specific product on the condition that it appear in the same location and at the same time as a specific article mentioning that product and they may not refer to an article published at the same time as the advertisement appears).
6. All advertisements for drug-specific campaigns must comply with the relevant local legislation that regulates advertising. Advertisers should make available to Publishers the marketing authorization and summary of product characteristics when submitting their advertisement. In the case of drug advertisements, the full generic name of each active ingredient should appear. Each page of an advertisement for a prescription-only medicine should be clearly labeled as intended for health professionals.
7. Advertisements and editorial content must be clearly distinguishable. Publishers will not publish “advertorial” content, and sponsored supplements must be clearly indicated as such. If a supplement did not undergo peer review or underwent a peer review-process different from the rest of the journal that should be explicitly stated.
8. Editorial decisions will not be influenced by current or potential sponsors and advertisers, and will not be influenced by marketing decisions. Advertisers and sponsors have no control or influence over the results of searches a user may conduct on the website by keyword or search topic.
9. If any advert is requested outside of Publishers standard advertising positions then a request should be made to editorial who will respond with a full and final decision within two business days.
ISSN 1867-416X (Print)
ISSN 1866-8836 (Online)